Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
Prediction of drug combinations that effectively target cancer cells is a critical challenge for cancer therapy, in particular for triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype with no effective targeted treatment. As signalling pathway networks critically control c...
Main Authors: | Sung-Young Shin, Anna-Katharina Müller, Nandini Verma, Sima Lev, Lan K Nguyen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-06-01
|
Series: | PLoS Computational Biology |
Online Access: | https://doi.org/10.1371/journal.pcbi.1006192 |
Similar Items
-
Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
by: Rajeshwari Mehta, et al.
Published: (2013-01-01) -
Targeting EGFR in Triple Negative Breast Cancer
by: Naoto T. Ueno, Dongwei Zhang
Published: (2011-01-01) -
Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
by: Aleksandra Simiczyjew, et al.
Published: (2018-09-01) -
MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells
by: Kamila Kitowska, et al.
Published: (2021-04-01) -
Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
by: Vanessa Y. C. Sung, et al.
Published: (2021-03-01)